Jim Cramer says ‘Covid winners’ like DocuSign still have time to reinvent themselves

Jim Cramer says ‘Covid winners’ like DocuSign still have time to reinvent themselves


CNBC’s Jim Cramer on Tuesday lamented the languishing stocks of pandemic winners like DocuSign — but suggested the window of reinvention has not been slammed shut just yet.

“We know it hasn’t been long since the pandemic effectively ended, but we’re so quick to fault the Fed for providing too much liquidity or Congress for doing too much deficit spending,” the “Mad Money” host said. “The truth is, we’d be in a much better situation if the private sector had been proactive about transitioning to a post-Covid world.”

Cramer highlighted a number of companies with Covid-fueled businesses that he believes have not done enough to thrive in an operating environment without significant public-health disruptions. He said he also puts Zoom Video, Clorox and Peloton within this classification, although he acknowledged at this point Peloton’s balance sheet complicates reinvention efforts.

Jim Cramer’s Guide to Investing

Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.

With DocuSign, for example, Cramer said he wishes the company used the roughly $1 billion in cash and short-term investments on its balance sheet to be more aggressive in the acquisitions realm.

“There are so many ancillary identity and cybersecurity deals they could’ve done that it is just painful,” he said. “The bottom line is that it’s not too late for some of these outfits, like Zoom, that are sitting on big piles of cash, to reinvent. They just can’t seem to point the camera at themselves and see the truth,” he added.



Source

Mercedes U.S. CEO sets ambitious sales goal despite ‘tougher’ market than anticipated
Business

Mercedes U.S. CEO sets ambitious sales goal despite ‘tougher’ market than anticipated

Mercedes-Benz USA CEO Adam Chamberlain said Tuesday that 2026 is shaping up to be more challenging than expected.   “If you look at the market in the first couple of months of the year, the market environment is definitely a little tougher than we anticipated,” Chamberlain told CNBC at the company’s manufacturing plant in Vance, […]

Read More
Nike is set to report earnings after the bell. Here’s what Wall Street expects
Business

Nike is set to report earnings after the bell. Here’s what Wall Street expects

A Nike logo is displayed at a Nike store on Feb. 5, 2026 in Austin, Texas. Brandon Bell | Getty Images Nike is expected to report a steep decline in quarterly profit and flat sales on Tuesday as the sneaker giant continues to work through a colossal turnaround under CEO Elliott Hill.  About a year […]

Read More
Lilly to spend up to .8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Business

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs

Eli Lilly Chair and CEO Dave Ricks speaks during a press conference in Houston, Texas, Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly has agreed to pay up to $7.8 billion to acquire Centessa Pharmaceuticals and its experimental drug for excessive daytime sleepiness, the company said Tuesday. Centessa is one of several companies working […]

Read More